Table 1.

Demographic and Clinical Characteristics of Patient Participants

Demographic variables	All patients (n = 81)
Age, mean (SD), y	51.1 (14.3)
Sex (male), n (%)	50 (62)
Marital status (married), n (%)	64 (79)
KPS, n (%), %
100	38 (47)
90	22 (27)
≤ 80	21 (26)
BMI, mean (SD)	26.9 (5.4)
Smoking, n (%)
Current	5 (6)
Previous	27 (33)
Never	30 (37)
Alcohol consumption (regular/occasional), n (%)	36 (44)
Clinical variables	All patients (n = 81)
Brain tumor type, n (%)
Primary	74 (91)
Grade IV	39 (53)
Grade III	15 (20)
Grade II	17 (23)
Other	3 (4)
Metastatic	7 (9)
Primary site (lung/breast)	4 (57)
Brain lesions (≥ 2)	6 (86)
Location, n (%)
Frontal	23 (28)
Temporal	20 (25)
Parietal	13 (16)
Occipital	2 (3)
Multiple	17 (21)
Other	6 (7)
Laterality, n (%)
Left	39 (49)
Right	31 (39)
Bilateral	10 (13)
Midline	1 (1)
Time since diagnosis, median (range), mo	12 (1-383)
Recurrence, n (%)	21 (26)
Progression in past 2 mo, n (%)	12 (15)
Treatment history, n (%)
Surgery	75 (93)
Biopsy only	9 (11)
Radiation	37 (46)
Chemotherapy	49 (61)
Radiation with concurrent chemotherapy	50 (62)
Other	4 (5)
No. of symptoms reported by clinician, n (%)
0	50 (62)
1	16 (20)
2	8 (10)
3+	7 (9)
History of psychological disorders	7 (9)
Type of common symptoms, n (%, of those presenting symptoms, n = 31)
Lethargy	11 (36)
Headache	9 (29)
Mood disturbance	6 (19)
Nocturnal urinary and neurological deficits	5 (16)
Involuntary movement	4 (13)
Medications	All patients (n = 81)
Medication for complications related to cancer, n (%)
Anticonvulsant	44 (54)
Antiemetic	29 (36)
Chemotherapy	35 (43)
Corticosteroid	20 (25)
Antidepressant	5 (6)
Benzodiazepine	8 (10)
PPI	12 (15)
Medication for comorbid illness, n (%)	21 (26)